Eli Lilly: Q2 Earnings Insights

Comments
Loading...

 

Shares of Eli Lilly LLY decreased 1.3% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 1.06% over the past year to $1.87, which missed the estimate of $1.92.

Revenue of $6,740,000,000 higher by 22.57% year over year, which beat the estimate of $6,650,000,000.

Outlook

The upcoming fiscal year's EPS expected to be between $7.80 and $8.00.

The upcoming fiscal year's revenue expected to be between $26,800,000,000 and $27,400,000,000.

Conference Call Details

Date: Aug 03, 2021

Time: 09:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/fy9ujkgu

Recent Stock Performance

Company's 52-week high was at $248.40

52-week low: $129.21

Price action over last quarter: Up 34.87%

Company Profile

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Overview Rating:
Speculative
50%
Technicals Analysis
100
0100
Financials Analysis
20
0100
Overview
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: